transthyretin amyloid cardiomyopathy
Cardiovascular · 2020–2026
2decisions
1medicine
1carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafamidis Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), specifically in patients with NYHA class I-II heart failure. | Mar 2026 | Not recommended | no section in document |
| tafamidis Treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with evidence of cardiac involvement by echocardiography and with a history of heart… | Jul 2020 | Not recommended | 10 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.